CytoSorbents Investor Relations
Honored with Frost & Sullivan’s Global Product Leadership Award for leading the critical-care immunotherapy segment in blood purification, CytoSorbents Corporation is currently distributing its EU-approved CytoSorb cytokine adsorber in 75 countries around the world
Featured News
CytoSorbents
Press Release
CytoSorbents Receives Approximately $1.7 Million from the New Jersey Business Tax Certificate Transfer Program
PRINCETON, N.J., April 21, 2025 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it has received $1.7 million in cash proceeds from the sale of its 2023 and amended 2022 Net Operating Loss (NOL) and ... CytoSorbents Receives Approximately $1.7 Million from the New Jersey Business Tax Certificate Transfer Program
CytoSorbents Appoints Melanie Grossman, CPA as Vice President and Corporate Controller
Ms. Grossman brings 25 years of accomplished finance and accounting experience in global, publicly-traded companies Company announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PRINCETON, N.J., April 17, 2025 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced ... CytoSorbents Appoints Melanie Grossman, CPA as Vice President and Corporate Controller
CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America
PRINCETON, N.J., April 14, 2025 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the appointment of Thomas Shannon as Vice President of Marketing for North America. With anticipated marketing approval, Mr. Shannon will lead the marketing ... CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America
CytoSorbents Extends Expiration Date of Outstanding Series B Right Warrants
PRINCETON, N.J., April 4, 2025 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced the extension of the expiration date of the Series B Right Warrants (the “Series B Right Warrants”) issued in the Company’s Rights Offering in ... CytoSorbents Extends Expiration Date of Outstanding Series B Right Warrants
Voices around the world
Featured Reports
Investor Presentation
May 2024
December 2024